We are live on ! Find out more
CRNX icon

Crinetics Pharmaceuticals
CRNX

140 hedge funds and large institutions have $974M invested in Crinetics Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 56 increasing their positions, 33 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 15

70% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 33

10% more capital invested

Capital invested by funds: $884M → $974M (+$89.8M)

9% more funds holding

Funds holding: 128 → 140 (+12)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

2.09% less ownership

Funds ownership: 102.14% → 100.05% (-2.1%)

93% less call options, than puts

Call options by funds: $32K | Put options by funds: $446K

Holders
140
Holders Change
+12
Holders Change %
+9.38%
% of All Funds
2.2%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
27
Increased
56
Reduced
33
Closed
15
Calls
$32K
Puts
$446K
Net Calls
-$414K
Net Calls Change
-$884K

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$27.7M
2
BlackRock
BlackRock
New York
+$12.8M
3
IC
Ikarian Capital
Texas
+$9.47M
4
Jennison Associates
Jennison Associates
New York
+$9.2M
5
PBA
Paradigm Biocapital Advisors
New York
+$5.21M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$44M
2
PA
Perceptive Advisors
New York
-$32.1M
3
B
Braidwell
Connecticut
-$27.3M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$3.64M
5
Walleye Capital
Walleye Capital
New York
-$2.39M
Name Holding Trade Value Shares
Change 		Change in
Stake
GKIM
26
GW&K Investment Management
Massachusetts
$10.6M +$974K +48,860 +9%
Dimensional Fund Advisors
27
Dimensional Fund Advisors
Texas
$9.35M +$1.39M +69,504 +15%
Northern Trust
28
Northern Trust
Illinois
$8.84M +$268K +13,442 +3%
MB
29
MPM BioImpact
Massachusetts
$8.63M +$2.37M +118,661 +33%
IC
30
Ikarian Capital
Texas
$8.56M +$9.47M +475,000 New
Janus Henderson Group
31
Janus Henderson Group
United Kingdom
$8.48M +$1.09M +54,484 +13%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$8.35M +$810K +40,629 +10%
Jennison Associates
33
Jennison Associates
New York
$8.32M +$9.2M +461,497 New
EAM
34
Eventide Asset Management
Massachusetts
$7.83M – – –
Charles Schwab
35
Charles Schwab
California
$6.32M +$103K +5,171 +1%
N
36
Nuveen
North Carolina
$6.18M +$4.36M +218,870 +176%
Walleye Capital
37
Walleye Capital
New York
$5.65M -$2.39M -120,097 -28%
Ensign Peak Advisors
38
Ensign Peak Advisors
Utah
$4.87M – – –
Citadel Advisors
39
Citadel Advisors
Florida
$4.36M -$875K -43,867 -15%
Adage Capital Partners
40
Adage Capital Partners
Massachusetts
$4.05M +$4.49M +225,000 New
ECM
41
ExodusPoint Capital Management
New York
$3.46M +$895K +44,858 +30%
First Manhattan
42
First Manhattan
New York
$2.74M – – –
Norges Bank
43
Norges Bank
Norway
$2.69M – – –
UBS Group
44
UBS Group
Switzerland
$2.63M +$1.73M +86,525 +146%
NLVP
45
New Leaf Venture Partners
New York
$2.54M – – –
Franklin Resources
46
Franklin Resources
California
$2.5M +$5.21K +261 +0.2%
Rafferty Asset Management
47
Rafferty Asset Management
New York
$2.49M +$189K +9,478 +7%
ACM
48
Altium Capital Management
New York
$2.43M +$698K +35,000 +35%
Bank of America
49
Bank of America
North Carolina
$2.17M -$1.12M -56,099 -32%
BFM
50
Boothbay Fund Management
New York
$1.74M +$1.93M +96,805 New
1
2
3 4 5

CRNX Hedge Fund Activity: Q2 2023 in Review

140 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q2 2023, worth a combined $974M — up 10% from $884M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new CRNX positions and 15 closed out — a net gain of 12 holders — while 56 added to existing stakes and 33 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $27.7M. The largest seller was BVF Inc, exiting entirely with an estimated $44M sold.

  • 140 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q2 2023, up from 128 in Q1 2023.
  • Funds reported $974M of Crinetics Pharmaceuticals stock for Q2 2023, up 10% quarter-over-quarter.
  • 27 funds opened new Crinetics Pharmaceuticals positions in Q2 2023 and 15 closed out, a net change of +12 holders.
  • The largest Crinetics Pharmaceuticals buyer in Q2 2023 was T. Rowe Price Associates, an estimated $27.7M added.
  • The largest Crinetics Pharmaceuticals seller in Q2 2023 was BVF Inc, an estimated $44M sold.

Based on aggregated 13F filings for Q2 2023.